Rhythm Pharmaceuticals (RYTM) Cash & Current Investments (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Cash & Current Investments data on file, last reported at $340.6 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 8.31% year-over-year to $340.6 million in Q1 2026; TTM through Mar 2026 was $340.6 million, a 8.31% increase from a year earlier, with the FY2025 full-year figure at $388.9 million, up 21.33% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $340.6 million, down from $388.9 million in the prior quarter.
• Over the last five years, Cash & Current Investments for RYTM reached as high as $780.1 million in Q3 2025 and fell as low as $201.7 million in Q1 2024.
• Historically, Cash & Current Investments has averaged $325.9 million across 5 years, with a median of $299.6 million in 2023.
• Across the five-year window, Cash & Current Investments tumbled 40.43% in 2022 and jumped 161.02% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $333.6 million in 2022, then decreased by 17.22% to $276.2 million in 2023, then increased by 16.07% to $320.6 million in 2024, then increased by 21.33% to $388.9 million in 2025, then decreased by 12.42% to $340.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $340.6 million in Q1 2026, $388.9 million in Q4 2025, and $780.1 million in Q3 2025.